Pharminent

AstraZeneca study shows cardiovascular benefit to SGLT-2 drugs

The British pharma hopes the results, assessed from real-world data, will help boost use of the newer class of diabetes drugs.  http://www.biopharmadive.com/news/astrazeneca-cvd-real-sglt2-diabetes-farxiga/438425/

Filed under: Diabetes, SGLT-2